Tools

LEADER 03593nam a2200529 i 4500

001 ssj0001569801;

003 WaSeSS;

005 20210412081717.0;

006 m d ;

007 cr n ;

008 150803s2015 nju s 001 0 eng d;

010 a| 2015030480;

020 a| 9781118914342 (epub);

020 a| 9781118819449 (pdf);

020 z| 9781118679678 (cloth);

035 a| (WaSeSS)ssj0001569801;

042 a| pcc;

049 a| EREEa| NEHH;

050 00 a| HD9665.5;

082 00 a| 615.1068/52| 23;

100 1 a| Alex, Alexander A.?| UNAUTHORIZED;

245 10 a| Attrition in the pharmaceutical industryh| [electronic resource] :b| reasons, implications, and pathways forward /c| edited by Alexander A. Alex, C. John Harris, Dennis A. Smith.;

260 a| Hoboken, New Jersey :b| John Wiley & Sons,c| 2015.;

300 a| 1 online resource.;

500 a| Includes index.;

505 0 a| Attrition in drug discovery and development / Scott Boyer, Clive Brealey and Andrew M. Davis -- Compound attrition at the pre-clinical phase / Cornelis E.C.A. Hop -- Attrition in phase I / Dennis A. Smith and Thomas A. Baillie -- Compound attrition in phase II/III / Alexander Alex, C. John Harris, Wilma W. Keighley and Dennis A. Smith -- Post-marketing attrition / Dennis A. Smith -- Influence of the regulatory environment on attrition / Robert T. Clay -- Experimental screening strategies to reduce attrition risk / Marie-Claire Peakman, Matthew Troutman, Rose Gonzales and Anne Schmidt -- Medicinal chemistry strategies to prevent compound attrition / J. Richard Morphy -- Influence of phenotypic and target-based screening strategies on compound attrition and project choice / Andrew Bell, Wolfgang Fecke and Christine Williams -- In silico approaches to address compound attrition / Peter Gedeck, Christian Kramer, Richard Lewis -- Current and future strategies for improving drug discovery efficiency / Peter Mbugua Njogu and Kelly Chibale -- Impact of investment strategies, organizational structure and corporate environment on attrition, and future investment strategies to reduce attrition / Geoff Lawton.;

506 a| Available only to authorized users.;

538 a| Mode of access: World Wide Web;

588 a| Description based on print version record and CIP data provided by publisher.;

650 0 a| Pharmaceutical industryx| Management.=| ^A1172692;

650 0 a| Pharmaceutical industryx| Capital productivity.=| ^A1297115;

650 0 a| Industrial efficiency.=| ^A349872;

650 0 a| Drug development.=| ^A443888;

655 0 a| Electronic books.=| ^A491897;

700 1 a| Harris, C. John.=| ^A1293453;

700 1 a| Smith, Dennis A.=| ^A1198423;

776 08 i| Print version:a| Alex, Alexander A., editor.t| Attrition in the pharmaceutical industryd| Hoboken, New Jersey : John Wiley & Sons, 2015z| 9781118679678w| (DLC) 2015024772;

856 40 z| Full text available from Ebook Central - Academic Completeu| https://ebookcentral.proquest.com/lib/eastcarolina/detail.action?docID=4435614;

949 a| CLICK ON WEB ADDRESSw| ASISh| JOYNER188;

949 a| CLICK ON WEB ADDRESSw| ASISh| HSL77;

949 a| CLICK ON WEB ADDRESSw| ASISh| JMUSIC60;

596 a| 1 3 4;

998 a| 5587471;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 5587471-1001l| JNETm| JOYNERr| Ys| Yt| JNESSBKu| 4/16/2021x| EBOOKz| JERESOURCE;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 5587471-2001l| HSLELECm| HSLr| Ys| Yt| HEBKu| 4/16/2021x| EBOOKz| HERESOURCE;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 5587471-3001l| MNETm| JMUSICr| Ys| Yt| MNESSBKu| 4/16/2021x| EBOOKz| JERESOURCE;

Attrition in the pharmaceutical industry reasons, implications, and pathways forward / edited by Alexander A. Alex, C. John Harris, Dennis A. Smith.

Author/creator	Alex, Alexander A.
Other author	Harris, C. John.
Other author	Smith, Dennis A.
Format	Electronic
Publication Info	Hoboken, New Jersey : John Wiley & Sons, 2015.
Description	1 online resource.
Supplemental Content	Full text available from Ebook Central - Academic Complete
Subjects	Pharmaceutical industry--Management. Pharmaceutical industry--Capital productivity. Industrial efficiency. Drug development.

Contents	Attrition in drug discovery and development / Scott Boyer, Clive Brealey and Andrew M. Davis -- Compound attrition at the pre-clinical phase / Cornelis E.C.A. Hop -- Attrition in phase I / Dennis A. Smith and Thomas A. Baillie -- Compound attrition in phase II/III / Alexander Alex, C. John Harris, Wilma W. Keighley and Dennis A. Smith -- Post-marketing attrition / Dennis A. Smith -- Influence of the regulatory environment on attrition / Robert T. Clay -- Experimental screening strategies to reduce attrition risk / Marie-Claire Peakman, Matthew Troutman, Rose Gonzales and Anne Schmidt -- Medicinal chemistry strategies to prevent compound attrition / J. Richard Morphy -- Influence of phenotypic and target-based screening strategies on compound attrition and project choice / Andrew Bell, Wolfgang Fecke and Christine Williams -- In silico approaches to address compound attrition / Peter Gedeck, Christian Kramer, Richard Lewis -- Current and future strategies for improving drug discovery efficiency / Peter Mbugua Njogu and Kelly Chibale -- Impact of investment strategies, organizational structure and corporate environment on attrition, and future investment strategies to reduce attrition / Geoff Lawton.
General note	Includes index.
Access restriction	Available only to authorized users.
Technical details	Mode of access: World Wide Web
Source of description	Description based on print version record and CIP data provided by publisher.
Issued in other form	Print version: Alex, Alexander A., editor. Attrition in the pharmaceutical industry Hoboken, New Jersey : John Wiley & Sons, 2015 9781118679678
Genre/form	Electronic books.
LCCN	2015030480
ISBN	9781118914342 (epub)
ISBN	9781118819449 (pdf)

Availability

Library	Location	Call Number	Status	Item Actions
	Electronic Resources	Access Content Online	✔ Available

Attrition in the pharmaceutical industry reasons, implications, and pathways forward / edited by Alexander A. Alex, C. John Harris, Dennis A. Smith.

Click here for more information about this title

Availability